Although PTPN11 inhibitors have shown promising effects in some cancers driven by aberrant RTK signalling or activated PTPN11, we did not observe a reduction of RMS559 viability when treating the cells with the SHP099 inhibitor. This evidence concerns the gene PTPN11 and cancer.